Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety ...

Let's look deeper into these results and what they could mean for investors. Novo Nordisk's weight loss candidate in question ...

After Novo Nordisk (NVO) reported that subcutaneous amycretin demonstrated up to 22% absolute weight loss at 36-weeks in a Phase 1/2a trial, BofA thinks this “looks potentially best in class.” The ...

Novo Nordisk A/S Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor ...

Novo Nordisk's weight loss candidate in question is called amycretin. The company is developing an oral and a subcutaneous version of this medicine. Amycretin is a GLP-1 agonist, but it also ...

Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...

Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once ...

NOW OPEN: 200 Charter Memberships to Benzinga Trade Alerts On Friday, Novo Nordisk A/S NVO released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous ...